Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 5/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19814711 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL8149970 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL1097570 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL856694 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL858969 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14946298 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14853815 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL19258430 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL2767589 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL7128636 | 1.00 | TK1 (0.47) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163250-B1 | IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES | EXIQON AS (DK) | 2006-07-12 | — | — | EP | disclosed |
| US-6639059-B1 | Novel synthesis strategy comprising novel key intermediate, (2.2.1)bicyclo nucleosides are produced at least two steps shorter than any previously known strategy; 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-alpha-D-ribofuranose | EXIQON A/S (DK) | 2003-10-28 | — | — | US | disclosed |
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | EXIQON A/S | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092905-A1 | Synthesis of [2.2.1]bicyclo nucleosides | NSUN2, RNGTT, RNMT | TK1 72/4885ALDH1A1 617/4885LMNA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.